Published in Hepatitis Weekly, May 31st, 2010
"The safety and efficacy of pioglitazone on insulin sensitivity and SVR in treatment-naive patients with chronic hepatitis C (CHC) genotype 4 with IR receiving standard antiviral therapy were evaluated in a randomized-controlled study. Ninety-seven previously untreated patients with CHC...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.